Avidity Biosciences Inc (RNA) concluded trading on Wednesday at a closing price of $44.63, with 4.72 million shares of worth about $210.44 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 87.60% during that period and on September 18, 2024 the price saw a gain of about 5.78%. Currently the company’s common shares owned by public are about 117.12M shares, out of which, 108.79M shares are available for trading.
Stock saw a price change of 10.09% in past 5 days and over the past one month there was a price change of -1.70%. Year-to-date (YTD), RNA shares are showing a performance of 393.15% which increased to 541.24% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.82 but also hit the highest price of $48.80 during that period. The average intraday trading volume for Avidity Biosciences Inc shares is 1.42 million. The stock is currently trading 5.33% above its 20-day simple moving average (SMA20), while that difference is up 2.18% for SMA50 and it goes to 67.85% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Avidity Biosciences Inc (NASDAQ: RNA) currently have 117.12M outstanding shares and institutions hold larger chunk of about 93.20% of that.
The stock has a current market capitalization of $5.23B and its 3Y-monthly beta is at 0.90. It has posted earnings per share of -$2.95 in the same period. It has Quick Ratio of 15.78 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RNA, volatility over the week remained 3.73% while standing at 4.40% over the month.
Stock’s fiscal year EPS is expected to drop by -0.08% while it is estimated to decrease by -7.22% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Barclays on August 28, 2024 offering an Overweight rating for the stock and assigned a target price of $63 to it. Coverage by BofA Securities stated Avidity Biosciences Inc (RNA) stock as a Buy in their note to investors on May 03, 2024, suggesting a price target of $40 for the stock. On March 14, 2024, Cantor Fitzgerald Initiated their recommendations, while on May 22, 2023, Evercore ISI Upgrade their ratings for the stock with a price target of $20. Stock get an In-line rating from Evercore ISI on March 31, 2023.
